IAN:CA:CNSX-iAnthus Capital Holdings Inc (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.015

Change

+0.01 (+50.00)%

Market Cap

USD 0.10B

Volume

6.08K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States. It offers cannabis flower and trims, such as packaged flowers and pre-rolls; cannabis infused products, including topical creams and edibles; vape cartridges, concentrates, live resins, wax products, oils, and tinctures, as well as products for beauty and skincare that include lotions, creams, haircare products, lip balms, and bath bombs. The company engages in the wholesale-distribution and retail of CBD products. iAnthus Capital Holdings, Inc. was founded in 2014 and is headquartered in Toronto, Canada. Address: 214 King Street West, Toronto, ON, Canada, M5H 3S6

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
GTII:CA Green Thumb Industries Inc

-0.04 (-0.25%)

USD 3.28B
TRUL:CA Trulieve Cannabis Corp

-0.07 (-0.43%)

USD 2.92B
CL:CA Cresco Labs Inc

-0.02 (-0.90%)

USD 0.77B
AYR-A:CA Ayr Wellness Inc

+0.01 (+0.41%)

USD 0.28B
PLTH:CA Planet 13 Holdings Inc

N/A

USD 0.26B
GRIN:CA Grown Rogue International Inc

+0.03 (+3.23%)

USD 0.21B
AAWH-U:CA Ascend Wellness Holdings Inc.

-0.02 (-2.50%)

USD 0.17B
JUSH:CA Jushi Holdings Inc

+0.06 (+9.23%)

USD 0.13B
MRMD:CA MariMed Inc.

N/A

USD 0.09B
FFNT:CA 4Front Ventures Corp

N/A

USD 0.06B

ETFs Containing IAN:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.14% 16% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.14% 16% F 25% F
Trailing 12 Months  
Capital Gain -50.00% 31% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.00% 31% F 34% F
Trailing 5 Years  
Capital Gain -99.22% 12% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.22% 12% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -24.13% N/A N/A 31% F
Dividend Return -24.13% N/A N/A 31% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 105.54% N/A N/A 25% F
Risk Adjusted Return -22.87% N/A N/A 51% F
Market Capitalization 0.10B 88% B+ 98% N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.